Alto Neuroscience, Inc. (ANRO)

Market Cap	382.29M
Revenue (ttm)	n/a
Net Income (ttm)	-36.31M
Shares Out	26.88M
EPS (ttm)	-9.73
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	114,893
Open	14.36
Previous Close	14.40
Day's Range	13.87 - 14.64
52-Week Range	12.78 - 24.00
Beta	n/a
Analysts	Strong Buy
Price Target	32.33 (+127.36%)
Earnings Date	May 14, 2024

About ANRO

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 2, 2024
• Country: United States
• Stock Exchange: NYSE
• Ticker Symbol: ANRO

Analyst Forecast

According to 3 analysts, the average rating for ANRO stock is "Strong Buy." The 12-month stock price forecast is $32.33, which is an increase of 127.36% from the latest price.

Price Target

$32.33

(127.36% upside)

Analyst Consensus: Strong Buy